{
    "nct_id": "NCT03085914",
    "official_title": "A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)",
    "inclusion_criteria": "* Histologically or cytologically confirmed diagnosis of selected advanced or metastatic solid tumors.\n* Presence of measurable disease per RECIST v1.1.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Laboratory and medical history parameters not within the Protocol-defined range.\n* Receipt of anticancer medications or investigational drugs within the Protocol-defined intervals before the first administration of study drug.\n* Previous radiotherapy within 2 weeks of starting study therapy.\n* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.\n* Has not recovered to â‰¤ Grade 1 from toxic effects of previous therapy and/or complications from previous surgical intervention before starting study therapy.\n* Receipt of a live vaccine within 30 days of planned start of study therapy.\n* Active infection requiring systemic therapy.\n* Subjects who have any active or inactive autoimmune disease or syndrome.\n* Women who are pregnant or breastfeeding.",
    "miscellaneous_criteria": ""
}